Content about Diabetic retinopathy

August 13, 2012

Regulators have approved a biotech drug made by Genentech for treating a complication related to diabetes.

SILVER SPRING, Md. — Regulators have approved a biotech drug made by Genentech for treating a complication related to diabetes.

The Food and Drug Administration approved Lucentis (ranibizumab) for diabetic macular edema, a cause of vision loss in people with diabetes. The drug already was approved for age-related macular degeneration.

July 27, 2012

A panel of Food and Drug Administration experts is recommending the approval of a drug made by Genentech for diabetic macular edema, the company said.

SILVER SPRING, Md. — A panel of Food and Drug Administration experts is recommending the approval of a drug made by Genentech for diabetic macular edema, the company said.

March 7, 2012

EyeScience Labs on Wednesday introduced a new eye vitamin for people with diabetes.

COLUMBUS, Ohio — EyeScience Labs on Wednesday introduced a new eye vitamin for people with diabetes.

October 28, 2011

A volunteer eye health and safety organization has introduced a new program that seeks to educate the public on the potential effects diabetes may have on one's vision.

CHICAGO — A volunteer eye health and safety organization has introduced a new program that seeks to educate the public on the potential effects diabetes may have on one's vision.

August 19, 2011

Americans that suffer from diabetes and/or hypertension are at risk of developing a common type of glaucoma, according to researchers at the University of Michigan Kellogg Eye Center.

NEW YORK — Americans that suffer from diabetes and/or hypertension are at risk of developing a common type of glaucoma, according to researchers at the University of Michigan Kellogg Eye Center.

April 8, 2011

Regeneron and Bayer HealthCare have initiated 1-of-2 late-stage clinical trials of their aflibercept ophthalmic solution in the treatment of a complication caused by diabetic retinopathy.

TARRYTOWN, N.Y. and BERLIN — Regeneron and Bayer HealthCare have initiated 1-of-2 late-stage clinical trials of their aflibercept ophthalmic solution in the treatment of a complication caused by diabetic retinopathy.

The drug makers said that it would evaluate the efficacy of VEGF Trap-Eye (aflibercept ophthalmic solution) in the treatment of diabetic macular edema, a prevalent cause of vision loss among diabetes patients, after promising results from its previous clinical trial.

March 31, 2011

Patients diagnosed with high blood-glucose levels that cannot control the condition over time likely will develop such eye-related complications as retinopathy 10 years later, according to a report in the February issue of Archives of Ophthalmology.

NEW YORK — Patients diagnosed with high blood-glucose levels that cannot control the condition over time likely will develop such eye-related complications as retinopathy 10 years later, according to a report in the February issue of Archives of Ophthalmology.

February 18, 2011

A drug used to treat high cholesterol, which will lose patent protection and face generic competition starting this year, also may help prevent blindness in people with diabetes, according to a study by researchers at the University of Georgia.

ATHENS, Ga. — A drug used to treat high cholesterol, which will lose patent protection and face generic competition starting this year, also may help prevent blindness in people with diabetes, according to a study by researchers at the University of Georgia.

February 14, 2011

Individuals who have higher blood-glucose levels and poorer control of those levels over time appear more likely to develop eye-related complications 10 years later, according to a report in the February issue of Archives of Ophthalmology published Monday.

CHICAGO — Individuals who have higher blood-glucose levels and poorer control of those levels over time appear more likely to develop eye-related complications 10 years later, according to a report in the February issue of Archives of Ophthalmology published Monday.

February 11, 2011

Genentech, a subsidiary of Roche, reported that its eye drug helped improve vision in patients suffering from a complication caused by diabetes.

SOUTH SAN FRANCISCO, Calif. — Genentech, a subsidiary of Roche, reported that its eye drug helped improve vision in patients suffering from a complication caused by diabetes.

In its phase-3 RISE study, Genentech said diabetic macular edema patients that received monthly Lucentis (ranibizumab injection) achieved an improvement in vision at 24 months, compared with placebo.

February 4, 2011

A drug designed to treat an eye condition caused by diabetes may provide a long-term option for patients, according to Alimera Sciences.

ATLANTA — A drug designed to treat an eye condition caused by diabetes may provide a long-term option for patients, according to Alimera Sciences.

Alimera said in two three-year, phase-3 pivotal clinical trials — collectively known as the FAME Study — of Iluvien, which is designed to treat diabetic macular edema, the drug improved visual acuity among patients.

January 3, 2011

The Food and Drug Administration declined to approve a treatment for diabetic eye disease made by Alimera Sciences, the drug maker said Dec. 23.

ATLANTA — The Food and Drug Administration declined to approve a treatment for diabetic eye disease made by Alimera Sciences, the drug maker said Dec. 23.

In its complete response letter, the FDA requested additional safety and efficacy data for the drug, Iluvien (fluocinolone acetonide intravitreal insert), a treatment for diabetic macular edema, a problem that commonly affects people with diabetes.

August 31, 2010

The Food and Drug Administration has granted priority review for a diabetic macular edema treatment....

ATLANTA The Food and Drug Administration has granted priority review for a diabetic macular edema treatment.

August 11, 2010

The prevalence of diabetic retinopathy, an eye disease caused by diabetes, has increased among diabetic...

WASHINGTON The prevalence of diabetic retinopathy, an eye disease caused by diabetes, has increased among diabetic adults in the United States, according to a study published in the Journal of the American Medical Association.

July 22, 2010

In high-risk adults with Type 2 diabetes, researchers have found that two therapies may slow...

WINSTON-SALEM, N.C. In high-risk adults with Type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

June 6, 2010

An investigational treatment for a complication of diabetes that often leads to blindness worked better...

May 31, 2010

Computerized systems may be able to detect early eye problems related to diabetes, according to...

NEW YORK Computerized systems may be able to detect early eye problems related to diabetes, according to a University of Iowa analysis.

May 2, 2010

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease and cataracts than...

BETHESDA, Md. Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease and cataracts than non-Hispanic whites, researchers that were part of the "Los Angeles Latino Eye Study" have found. According to a press release issued by the National Eye Institute on Saturday, these are the first estimates of visual impairment and eye disease development in Latinos.

May 2, 2010

A combination of a biotech drug and laser treatment may improve vision in patients with...

March 2, 2010

More than half the patients taking the low dose of a drug for diabetic macular...

January 12, 2010

African-American diabetics who consume large amounts of calories and sodium risk developing more severe retinal...